Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3127760 · 1 trial · 1 indication
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
| Arm | Type | Description |
|---|---|---|
| LY3127760 (Single) | EXPERIMENTAL | Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods. |
| Placebo (Single) | PLACEBO_COMPARATOR | Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance. |
| LY3127760 (Multiple) | EXPERIMENTAL | Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days. |
| Placebo (Multiple) | PLACEBO_COMPARATOR | Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance. |
| Celecoxib (Multiple) | ACTIVE_COMPARATOR | Multiple oral doses of 400 mg celecoxib administered QD for 28 days. |
| Name | Type | Description |
|---|---|---|
| LY3127760 | DRUG | Administered orally |
| Celecoxib | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy males or females as determined by medical history and physical examination * Male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product * Female participants not of chil...
LY3127760 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease or condition it is intended to treat has not been publicly disclosed.
LY3127760 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in the United States.
LY3127760 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA for any indication.
LY3127760 has been evaluated in one clinical trial, NCT01968070, titled A Study of LY3127760 in Healthy Participants. The Phase 1 trial enrolled 80 healthy volunteers in the United States, was randomized, double-blind, and placebo-controlled, and is now completed.
The Phase 1 trial NCT01968070 studied LY3127760 in 80 healthy adult volunteers aged 18 years and older in the United States. It was a randomized, double-blind, placebo-controlled study, and it has been completed. No efficacy results in patients have been reported.